FIB 918
Alternative Names: FIB-918Latest Information Update: 17 Jun 2026
At a glance
- Originator Fibrocor Therapeutics
- Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
- Mechanism of Action Integrin modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatic fibrosis; Pulmonary fibrosis; Renal fibrosis
- Discontinued Hereditary nephritis
Most Recent Events
- 17 Jun 2026 Discontinued - Preclinical for Hereditary nephritis in Canada (Parenteral) (Fibrocor Therapeutics Pipeline, June 2026)
- 17 Jun 2026 Preclinical trials in Hepatic fibrosis in Canada (Parenteral), prior to June 2026 (Fibrocor Therapeutics Pipeline, June 2026)
- 17 Jun 2026 Preclinical trials in Pulmonary fibrosis in Canada (Parenteral), prior to June 2026 (Fibrocor Therapeutics Pipeline, June 2026)